38
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

      correction

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Erratum Following publication of our article [1] we identified an error in Fig. 5, where results were inadvertently switched between morning and evening PEF responses. The corrected Fig. 5 is provided in this erratum. The PEF results provided in our original article text remain correct. Fig. 5 Morning and evening PEF response after 4 weeks of treatment (full analysis set). Adjusted for ‘treatment’, ‘period’, ‘patient’ and ‘baseline’. *p < 0.05 versus placebo Respimat®. PEF, peak expiratory flow

          Related collections

          Most cited references1

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

          Background A considerable number of children with asthma remain symptomatic despite treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, increased healthcare costs and lost school days. The aim of our study was to assess the efficacy, safety and tolerability of once-daily tiotropium Respimat® 5 μg, 2.5 μg and 1.25 μg add-on to medium-dose inhaled corticosteroids, with or without a leukotriene modifier, in children aged 6–11 years with symptomatic asthma. Methods In this Phase II, double-blind, placebo-controlled, incomplete-crossover, dose-ranging study, patients were randomised to receive three of the four treatments evaluated: once-daily tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg or placebo Respimat®, in the evening during the 12-week (three × 4-week) treatment period. Results In total, 76, 74, 75 and 76 patients aged 6–11 years received tiotropium Respimat® 5 μg, 2.5 μg, 1.25 μg and placebo Respimat®, respectively. For the primary end point (peak forced expiratory volume in 1 second measured within 3 hours post-dosing), the adjusted mean responses with tiotropium Respimat® 5 μg (272 mL), 2.5 μg (290 mL) and 1.25 μg (261 mL) were significantly greater than with placebo Respimat® (185 mL; p = 0.0002, p < 0.0001 and p = 0.0011, respectively). The safety and tolerability of all doses of tiotropium Respimat® were comparable with those of placebo Respimat®, with no serious adverse events and no events leading to discontinuation. Conclusions Tiotropium Respimat® add-on to medium-dose inhaled corticosteroids, with or without a leukotriene modifier, was efficacious in paediatric patients with symptomatic asthma and had comparable safety and tolerability with placebo Respimat®. Trial registration ClinicalTrials.gov identifier NCT01383499 Electronic supplementary material The online version of this article (doi:10.1186/s12931-015-0175-9) contains supplementary material, which is available to authorized users.
            Bookmark

            Author and article information

            Contributors
            christian.vogelberg@uniklinikum-dresden.de
            Journal
            Respir Res
            Respir. Res
            Respiratory Research
            BioMed Central (London )
            1465-9921
            1465-993X
            20 October 2015
            20 October 2015
            2015
            : 16
            : 128
            Affiliations
            [ ]University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany
            [ ]Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
            [ ]Vilnius University Hospital, Vilnius, Lithuania
            [ ]Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
            [ ]Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany
            [ ]Department of Pediatrics, Children’s Hospital of Colorado and the University of Colorado Denver School of Medicine, Aurora, Colorado USA
            Article
            290
            10.1186/s12931-015-0290-7
            4618361
            26487277
            f90fe245-66f7-437d-b290-3d24a4c42f02
            © Vogelberg et al. 2015

            Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

            History
            : 12 October 2015
            : 12 October 2015
            Categories
            Erratum
            Custom metadata
            © The Author(s) 2015

            Respiratory medicine
            Respiratory medicine

            Comments

            Comment on this article